DMAA signs LOI for de-SPAC merger with Power Analytics Global Corp at ~$1B valuation

Drugs Made In America Acquisition Corp.

Non-binding letter of intent signed April 7, 2026, with target Power Analytics Global Corp (Delaware).
Implied equity valuation of approximately $1.0 billion, subject to due diligence and adjustments.
Minimum cash condition expected in range of $25 million to $50 million, subject to redemptions.
Parties will negotiate definitive business combination agreement; deal to result in PAGC becoming public.
DMAA may seek stockholder approval to extend business combination deadline; sponsor support possible.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.